Shukra Pharmaceuticals Enters Strategic Joint Venture with Borns Medical Robotics for Surgical AI Systems in India and APAC
Shukra Pharmaceuticals Limited has signed a Term Sheet with Borns Medical Robotics Pte Ltd, Singapore, to establish a strategic joint venture focused on designing, manufacturing, distributing, and servicing AI-enabled surgical robotic systems across India and the Asia-Pacific region.The partnership aims to build a comprehensive platform for surgical robotics within India, progressing through localization of manufacturing and expansion into the APAC market.
Key particulars of the Term Sheet set out the structure and commercial framework for this proposed venture. The agreement was executed on August 13, 2026.
Strategic Partnership Details
The joint venture intends to create B&S Robotics Private Limited (B&S India) in India. This collaboration combines specialized technology with established market capabilities to drive growth in the advanced medical device sector.A summary of the principal terms and details of the agreement is presented below:
| Particulars | Details |
|---|---|
| Name(s) of Parties | Shukra Pharmaceuticals Limited and Borns Medical Robotics Pte Ltd / proposed Singapore incorporated holding entity of Borns Medical Robotics |
| Purpose of Agreement | To establish a strategic joint venture for designing, manufacturing, distributing, and servicing AI-enabled surgical robotic systems in India and the Asia-Pacific region. Post USFDA/CE certificate completion, expansion into the rest of the world will follow. |
| Nature of Agreement | Strategic Joint Venture Term Sheet / Heads of Terms outlining the principal commercial and legal framework for the proposed joint venture and subsequent definitive agreements. |
| Date of Execution | August 13, 2026 |
Contributions and Governance Structure
The partnership defines clear roles and responsibilities across technology transfer, market access, and business execution.Shukra's contributions include capital investment, leveraging its distribution network, industry-led team, market development capabilities, branding support, infrastructure initiatives, and the financing ecosystem. Borns is set to provide its technology platform and surgical robotic systems, along with relevant technical expertise, manufacturing know-how, and related capabilities, as per the definitive agreements.
The proposed ownership structure for the Indian joint venture entity, B&S Robotics Private Limited, stands at 60% for Shukra and 40% for Borns Singapore.
| Area | Details |
|---|---|
| Proposed JV Entity Name | B&S Robotics Private Limited (B&S India) in India |
| Nature of Business | Design, manufacture, distribution, and servicing of AI-enabled surgical robotic systems, including related instruments, consumables, software, and services within the approved field of use and territory. |
| Governance Structure | The proposed Board for B&S India is contemplated to consist of five directors: three nominated by Shukra and two by Borns Singapore. Detailed governance will be captured in the Shareholders' Agreement and Articles of Association. |
Timeline and Prerequisites
The venture is subject to several conditions precedent, including mutual due diligence, independent valuation, and necessary regulatory and corporate approvals (such as FEMA/FDI confirmations). The parties plan for the execution of definitive agreements within approximately 120 days from the Term Sheet date.Material terms contemplated by the Term Sheet include incorporating B&S India and B&S Singapore Pte Ltd., investment by Borns Singapore, IP licensing arrangements, technology transfer/localization commitments, governance structures, royalty arrangements, and a potential future demerger or listing pathway.
The immediate financial commitment is not fixed; the initial paid-up capital of B&S India is yet to be determined under the definitive agreements. The transaction is currently viewed as being outside the ordinary course of business for Shukra Pharmaceuticals Limited.
SHUKRAPHAR Stock Price Movement
Today, Shukra Pharmaceuticals Ltd.'s stock edged higher in post-market trading, finishing with a 0.61% gain and settling near the indicative close of ₹41.49. Trading activity saw the shares fluctuate within a range bounded by the low of ₹40.06 and the high of ₹43.4, while 995,399 shares were exchanged during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: